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Hypertrophic cardiomyopathy (HCM) is the most common single gene inherited
cardiomyopathy. In cats (Felix catus) HCM is even more prevalent and affects 16% of the
outbred population and up to 26% in pedigree breeds such as Maine Coon and Ragdoll.
HomozygousMYBPC3mutations have been identified in these breeds but the mutations
in other cats are unknown. At the clinical and physiological level feline HCM is closely
analogous to human HCM but little is known about the primary causative mechanism.
Most identified HCM causing mutations are in the genes coding for proteins of the
sarcomere. We therefore investigated contractile and regulatory proteins in left ventricular
tissue from 25 cats, 18 diagnosed with HCM, including a Ragdoll cat with a homozygous
MYBPC3 R820W, and 7 non-HCM cats in comparison with human HCM (from septal
myectomy) and donor heart tissue. Myofibrillar protein expression was normal except
that we observed 20–44% MyBP-C haploinsufficiency in 5 of the HCM cats. Troponin
extracted from 8 HCM and 5 non-HCM cat hearts was incorporated into thin filaments
and studied by in vitro motility assay. All HCM cat hearts had a higher (2.06 ± 0.13
fold) Ca2+-sensitivity than non-HCM cats and, in all the HCM cats, Ca2+-sensitivity was
not modulated by troponin I phosphorylation. We were able to restore modulation of
Ca2+-sensitivity by replacing troponin T with wild-type protein or by adding 100 µM
Epigallocatechin 3-gallate (EGCG). These fundamental regulatory characteristics closely
mimic those seen in human HCM indicating a common molecular mechanism that is
independent of the causative mutation. Thus, the HCM cat is a potentially useful large
animal model.
Keywords: Felix catus, Ragdoll cat, hypertrophic cardiomyopathy, cardiac muscle, Ca2+ regulation, troponin,
phosphorylation, uncoupling/recoupling
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INTRODUCTION
Feline HCM Mutations and Incidence
Hypertrophic cardiomyopathy (HCM) is identified in about 1
in 500 people. It is the leading cause of sudden cardiac death
in young adults and results in significant disability in survivors.
Mutations in at least 14 genes encoding proteins of the cardiac
sarcomere (with over 1,400 variants) are associated with HCM.
In most cases, HCM is inherited as an autosomal dominant
trait with variable penetrance (Maron et al., 2014), although the
causative mutation cannot be identified in about half of the cases.
This may be explained by either existence of rare sarcomeric
or non-sarcomeric genetic variants, the influence of modifier
genes or the presence of phenocopies (Maron et al., 2010; Lopes
et al., 2015). Alterations in two genes, β-myosin heavy chain and
myosin-binding protein C (MYBPC3) account for∼75% of cases
where an underlying mutation has been identified (Alfares et al.,
2015).
HCM has an exceedingly high prevalence in cats, affecting
∼16% of the outbred population (Paige et al., 2009; Payne et al.,
2015). This prevalence increases in pedigree breeds such as the
Maine Coon where it is estimated at 26% (Gundler et al., 2008).
A heritable component for HCM, has also been described in
Ragdoll, Siberian, Sphynx, American Shorthair, Cornish Rex,
Persian, European, British Shorthair, Bengal, Chartreux, and
Norwegian Forest cats (Trehiou-Sechi et al., 2012; Longeri et al.,
2013; März et al., 2014). Despite this, causative mutations have
only been identified in Maine Coon and Ragdoll cats. In both
breeds, a homozygous mutation in MYBPC3 was identified
resulting in amino acid substitution—A31P and R820W inMaine
Coons and Ragdolls, respectively (Meurs et al., 2005, 2007). The
same R820W mutation has been identified in a human family
which exhibits an almost identical phenotype to Ragdoll cats with
severe left ventricular wall hypertrophy, arrhythmia, congestive
heart failure and sudden cardiac death in homozygotes and only
mild and very late expression in heterozygous carriers (Ripoll
Vera et al., 2010; Borgeat et al., 2014). Despite analysis of
candidate genes in a number of other pedigree breeds no other
mutations have been identified to date (Meurs et al., 2009). There
is also limited information regarding the influence of modifier
genes on left ventricular (LV) hypertrophy (Borgeat et al., 2015)
or the presence of phenocopies in the feline population.
Feline HCM Characteristics and
Similarities with Human
Feline HCM closely resembles the comparable human condition
with respect to many clinical and pathologic features, and
therefore represents an important spontaneously occurring
animal model (Kittleson et al., 1999; Maron and Fox, 2015). At
the clinical level, feline HCM is a heterogeneous disease, both in
terms of presentation and outcome.
Many cats present with signs of congestive heart failure,
others die suddenly; however, the majority can have long
survival times and die of non-cardiac causes (Rush et al.,
2002). Prognostic indicators associated with an increased risk of
cardiac death are similar to those identified in human patients
and included arrhythmia, extreme left ventricular hypertrophy,
reduced atrial and ventricular systolic function, regional wall
hypokinesis and a restrictive diastolic filling pattern (Payne
et al., 2013). That said, inter-species differences are evident, for
instance feline HCMmore frequently results in progressive heart
failure or arterial thromboembolism as the major complication
(Borgeat et al., 2014; Maron and Fox, 2015). The incidence of
sudden unexpected death associated with feline HCM has not
been fully evaluated in cats but may be lower than seen in
human patients (Maron and Fox, 2015; Wilkie et al., 2015).
In both species, myofiber disarray, intramural coronary artery
disease, interstitial and replacement fibrosis are the hallmarks
of HCM on histopathology (Liu et al., 1993; Wilkie et al.,
2015). Furthermore, in both humans and cats HCM results
in significant diastolic dysfunction, however, both species can
develop end-stage cardiomyopathy as part of the natural course
of disease, where pathologic remodeling includes left ventricular
chamber dilation, wall thinning, and fibrosis (Cesta et al.,
2005).
Current Studies on Function in HCM
Despite progress in elucidating the genetic basis of HCM,
there is less understanding of the molecular events that lead
from mutation to disease phenotype (Lopes and Elliott, 2014).
Development of hypertrophy is a late stage event in HCM,
resulting from detrimental processes, which operate during the
pre-hypertrophic stage of the disease (Cannon et al., 2015).
Studies on septal myectomy tissue from human patients with
HCM and from engineered rodent models indicate that the
majority of sarcomeric mutations enhance myofilament Ca2+-
sensitivity leading to a hypercontractile phenotype with energy
deficiency and altered Ca2+ handling which act as the major
common pathways promoting HCM (Huke and Knollmann,
2010; Marston, 2011; Song et al., 2013). Given the striking
similarities between the human and feline disease outlined above,
it is likely that similar common pathways initiate and drive a
significant proportion of the HCM phenotype in cats. Although,
contractile and electrophysiological properties of ventricular
cardiomyocytes isolated from clinically normal cats and those
exposed to pressure loading techniques have been assessed
in detail over the last three decades (Kleiman and Houser,
1988; Weisser-Thomas et al., 2005), there remains a sparsity
of information concerning the effect of HCM on contractile
function in feline cardiomyocytes.
We therefore studied contractile and regulatory proteins
in left ventricular tissue from a range of cats with and
without evidence of HCM on echocardiography and/or
histopathology. These included pure-bred cats such as Ragdoll
with and without the homozygous R820W mutation and a
number of outbred cats with unknown mutations. Feline
samples were compared with myectomy samples from human
patients.
We measured protein expression, troponin I and MyBP-C
phosphorylation levels and isolated troponin from cat heart
muscle and investigated regulation by in vitromotility assay.
We found that fundamental Ca2+-regulatory abnormalities
in cats are virtually the same as in humans indicating this as a
potentially useful animalmodel of hypertrophic cardiomyopathy.
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METHODS
Cat Heart Collection Methods
This study was approved by the Royal Veterinary College (RVC)
institutional ethics and welfare committee, and written owner
consent for study participation was obtained. Full thickness
feline myocardium was harvested from the left ventricular
(LV) free wall immediately following euthanasia and placed
into a pre-cooled tube on dry ice and then transferred within
30 min to a −80◦C freezer or stored in liquid nitrogen at
below −160◦C. Samples obtained from outside the RVC were
frozen at −20◦C for a maximum of 2 weeks before being
transferred to the RVC on dry ice for storage. Cats with HCM
were euthanized either for intractable heart failure or aortic
thromboembolism. Non-HCM cats were euthanized for a
variety of reasons including neoplasia, acute kidney injury, and
dementia. HCM was diagnosed either by echocardiography or
by necropsy/histopathology or both (Figure 1). Full clinical
details including treatment at the time of death were available for
all feline cases in this study. Echocardiography was performed
either using a GE Vivid-7 ultrasound machine with a 7.5 mHz
transducer or where the cat was too unstable, a cage side
exam was performed using a GE Vivid-I portable ultrasound
machine (GE Systems Ltd., Hatfield, United Kingdom) with a
7.5 mHz transducer. All LV wall thickness measurements were
made from 2-D recorded images. Maximal LV wall thickness
in diastole was measured on the last frame before mitral valve
closure on images where the mitral valve was visible and at
the time point in the cardiac cycle of greatest LV internal
diameter on images where the mitral valve was not visible.
A leading-edge-to-trailing-edge method of measurement was
used, being careful to exclude the pericardium, false tendons
or papillary muscles, but including the endocardial borders
(Lang et al., 2005). A diagnosis of HCM was made if the LV
wall thickness exceeded 6 mm in the absence of predisposing
factors such as aortic stenosis and systemic arterial hypertension
(Fox et al., 1995). A record of the pattern of LV hypertrophy
(global or regional) was made (Table 1). Pathological assessment
consisted of gross pathology and in the majority of cases also
histopathology. Briefly, a semi-quantitative scoring system was
used to grade histopathologic criteria as previously described
(Wilkie et al., 2015). Morphological lesions assessed included
myocyte hypertrophy, myofiber disarray, fibrosis (interstitial,
perivascular, replacement, subendocardial), inflammatory cell
infiltrate, intramural arteriolosclerosis, myocyte degeneration,
and fat infiltration. The certainty of diagnosis (HCM or non-
HCM) for each sample used in the study was scored using the
following criteria. ∗∗∗HCM or non-HCM heart unequivocally
diagnosed by echocardiography and by pathological assessment
with appropriate clinical signs. ∗∗HCM or non-HCM heart
unequivocally diagnosed by either echocardiography or
pathological assessment with appropriate clinical signs. ∗Either
equivocal findings on echocardiography and or pathology
or neither echocardiography nor pathology performed but
the cat must have had appropriate clinical signs. Equivocal
findings included, emergency cage side echocardiography which
was not detailed enough to allow for accurate assessment of
LV morphology and histopathological changes which were
considered too minor to be diagnostic.
Myectomy and Donor Collection Methods
Human myocardial samples were obtained from patients with
hypertrophic obstructive cardiomyopathy (HOCM) undergoing
surgical septal myectomy for relief of left ventricular outflow
tract obstruction (LVOTO). Local ethical approval was obtained
from University College London Hospitals and the Brompton,
Harefield, and NHLI ethics committees for collection and use of
tissue samples (for clinical details, see Supplementary Table S1).
Donor hearts had no history of cardiac disease and normal
ECG and ventricular function and were obtained when no
suitable transplant recipient was found. Approval was granted by
the Human Research Ethics Committees of both the University of
Sydney (Protocol No. 2814) and St. Vincent’s Hospital (Protocol
No. H91/048/1a) for the collection and distribution of the human
heart samples and by the NHS National Research Ethics Service,
South West London REC3 (10/H0803/147) for study of the
samples. Patients gave written consent with PIS approved by
the relevant ethical committee. All samples are anonymised. The
investigations conform to the principles of the Declaration of
Helsinki. These samples have been previously described (Messer
et al., 2009, 2016; Copeland et al., 2010; Bayliss et al., 2012).
Identification of MYBPC3 A31P and R820W
Mutations
The known cat HCM-causing mutations were identified using a
PCR based assay to test for the mutation using DNA extracted
from either blood pellets or buccal mucosal swabs. The tests were
performed by Langford Diagnostic Laboratories, University of
Bristol Faculty of Veterinary Medicine.
Isolation of Myofibrils, MyBP-C
Quantification
Whole tissue extracts were obtained for gel electrophoresis using
T-Per Protein extraction reagent (Pierce, Thermo Scientific)
including 1 µg/ml E64, chymostatin, and leupeptin protease
inhibitors according to the manufacturer’s protocol. The
myofibrillar fraction of heart muscle was prepared by our
standard protocol (Messer et al., 2007) and analyzed by SDS-
PAGE (Bio-Rad Criterion Criterion TGXTM gradient gel 4–
15%) stained with SYPRO Ruby protein stain or in Western
blots using mouse anti-MyBP-C F5 (GE Healthcare) (1/1,000
dilution), anti-TnI clone 14G5 (Abcam), and mouse EA-53
anti-α-actinin antibody (Sigma) (1/2,000), visualized with ECL
Western Blotting Detection Reagent (GE Healthcare).
The level of phosphorylation of troponin I (TnI) and MyBP-
C in myofibrils and troponin was measured by phosphate affinity
SDS-PAGE as shown in Supplementary Data 1 using the methods
of Messer et al. (2009) for TnI and Copeland et al. (2010) for
MyBP-C.
Troponin was isolated from cat heart muscle myofibrils,
using an anti-cTnI monoclonal antibody affinity column as
described by Messer et al. (2007). This yields pure and active
troponin, which is usable for 3 days in an in vitro motility assay
(IVMA). Where appropriate, troponin was dephosphorylated
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FIGURE 1 | Histopathology and echocardiography characterization of HCM cats. Histopathology sections from HCM cat H11: (a) Myofibre disarray and sarcoplasmic
fragmentation (H+E). (b) Intramural fibrosis with myofibre disarray and fragmentation of sarcoplasm (Masson’s Trichrome). (c) Fibrosis in a papillary muscle (Masson’s
Trichrome). (d) Arteriosclerosis (H+E). Echocardiography of cat hearts N4 and H14. NON-HCM Cat (e). Right parasternal long axis view of cat N4 at end diastole.
Note normal sized LA (green arrow) and LV wall thickness (red arrows) measuring <6 mm (see accompanying movie S1). (f) Right parasternal short axis view at the
level of the papillary muscles of cat N4 at end diastole. Note normal LV wall thickness (red arrows) measuring <6 mm. HCM Cat (g) Right parasternal long axis view
of cat H14 at end diastole. Note severe hypertrophy of the LV free wall measuring >6 mm (double headed arrow) and a small volume pericardial effusion secondary to
heart failure (green arrow). An incidental false tendon (single headed red arrow) is also present (see accompanying movie S2). (h) Right parasternal long axis view of
cat H14 at end systole. Note the severely enlarged LA (double headed arrow). Further echocardiography plots and movies in supplementary Data.
by treatment with shrimp alkaline phosphatase (Sigma, P9088)
and phosphorylation levels were increased by treatment with
protein kinase A (PKA) catalytic subunit (Sigma, P2645-400).
Recombinant human cardiac troponin T was exchanged into cat
heart troponin following the procedures and controls previously
described (Messer et al., 2007, 2016; Bayliss et al., 2012; Memo
et al., 2013).
Quantitative In vitro Motility Assay (IVMA)
Thin filaments were reconstituted with 10 nM rabbit skeletal or
mouse cardiac muscle α-actin (labeled with TRITC phalloidin),
tropomyosin (60 nM), and troponin (60 nM) to study Ca2+-
regulation of filamentmotility by the quantitative in vitromotility
assay (IVMA; Fraser and Marston, 1995; Messer et al., 2007).
Thin filament movement over a bed of immobilized rabbit fast
skeletal muscle heavy meromyosin (100 µg/ml) was compared
in paired motility chambers in which troponin varied by a
single factor (mutation, phosphorylation state, or treatment with
drug). The temperature was set to 29◦C. Filament movement
was recorded and analyzed as previously described (Marston
et al., 1996) yielding two parameters; the fraction of filaments
moving and the speed of moving filaments. These parameters
were measured over a range of Ca2+ concentrations to generate
Ca2+-activation curves as shown previously (Memo et al., 2013;
Papadaki et al., 2015). The data were fitted to the four-variable
Hill equation to yield a value for EC50 and nH . EC50-values from
replicate experiments were analyzed by paired t-test since the
distribution of EC50 has been shown to be normal.
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RESULTS
Cat Heart Samples
We sourced 18 cardiac samples from cats treated at the RVC and
7 from collaborating veterinary practices. Non-HCM samples
were collected from patients euthanized for non-cardiac reasons.
Samples were cooled (QMHA: −80◦C, collaborating practices:
−20◦C) and stored at −80◦C or in liquid nitrogen at below
−160◦C. All available data for the samples is collated in
Table 1. We made a careful examination of the clinical records,
particularly echocardiography and histology data, and scored the
strength of HCM or non-HCM diagnosis for this cat population
using the criteria described in the methods section. Examples
of echocardiography and histological sections are shown in
Figure 1 and additional echocardiography scans are shown in
Supplementary Data 3 and in the Supplementary movies. All the
samples were studied by gel electrophoresis and eight HCM cats
and five non-HCM cats with the highest certainty of diagnosis
were selected for further investigation by in vitro motility assay
(IVMA).
The majority of the cats studied were outbred domestic
shorthaired animals but we also studied samples from pedigree
cats with HCM including Ragdoll, Maine Coon, British Short
Hair, and Norwegian Forest breeds with established high
prevalence of inherited HCM. The homozygous MYBPC3
R820Wmutation was identified in one Ragdoll cat sample.
Cat Heart Contractile Proteins
Figure 2 shows examples of SDS-PAGE of the myofibrils
extracted from our collection of cat hearts in comparison
with a human heart sample (NH). All the expected contractile
proteins were identified in the cat samples in the appropriate
proportions. Observation of the feline band patterns showed no
signs of protein degradation (band streaking, high background
or fragmented bands). H10L and H10RT are two left ventricular
samples from the same cat with H10RT left at room temperature
for 90min post-excision before freezing. Comparison of the band
patterns showed there was no indication of protein degradation
after this treatment.
Since the onlyHCM-causingmutations so far identified in cats
are in the MYBPC3 gene and because most MYBPC3 mutations
associated with HCM in humans result in haploinsufficiency, we
determined the quantity of MyBP-C relative to the constitutive
protein α-actinin.
The average cMyBP-C/α-actinin ratio in each lane was
normalized against the average value for the non-HCM cats. In
the HCM cat samples we found that five samples (H6, H7, H8,
H10, and H14) have significantly lower cMyBP-C content when
compared to non-HCM samples (Figure 3A). In addition, H16
exhibits a marked reduction approaching significance in one-way
ANOVA. The percentage decrease of cMyBP-C was around 20%
in the majority of deficient samples (H6, H8, H10, and H16), but
two samples had a much lower content, H7 (30%) and H14 (44%)
(Table 2). Of the deficient samples 4 were domestic shorthair
(DSH), one (H6) was a Bengal, and one (H16) was a Maine
Coon (without the MYBPC3 A31P mutation). Interestingly, H5
(the Ragdoll cat genotyped to be homozygous for the MYBPC3
R820W mutation) did not exhibit a cMyBP-C deficiency, even
when compared to H17 (a Ragdoll cat without the MYBPC3
R820Wmutation) in a one-way T-test. In Western blots, none of
the samples showed any lower molecular weight bands that could
be truncated peptides (Supplementary Data 2).
Phosphorylation Level of MyBP-C and TnI
Is Not Significantly Changed in the
Myocardium of HCM Cats
Protein phosphorylation levels were determined by phosphate
affinity SDS-PAGE. Cat cMyBP-C phosphorylation data is
presented in Figure 3B. The overall phosphorylation of the non-
HCM cat samples was 3.03 ± 0.37 mols Pi/mol (n = 4), which
compares with 2.70 ± 0.07 mols Pi/mol reported in human
FIGURE 2 | SDS-PAGE of cat and human myofibrillar fraction. NH is a human heart sample for comparison. The green bar shows the non-HCM cat myofibrils
(N1-N9) and the red bar shows the HCM cat myofibrils (H1-H19) (see Table 1). All myofibrils are from left ventricular heart samples, except for H10, H11, H12, and
H17 where both left (L) and right (R) ventricular samples are shown. H10RT is a portion of the H10L sample, which was left for 90 min post-excision before freezing.
Stars show samples used for IVMA studies.
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FIGURE 3 | MyBP-C content, MyBP-C phosphorylation and Troponin I phosphorylation in cat heart muscle samples. (A) Histogram showing the MyBP-C content of
the cat samples based on analysis of multiple SDS-PAGE gels similar to those in Figure 2. The normalized ratio of MyBP-C band to α-actinin is plotted as the mean
and standard deviation of at least 6 replicate lanes for each sample. Non-HCM and HCM cat samples were compared by one-way ANOVA and 5 samples showed
significant haploinsuffficiency. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. (B) Histogram of the phosphorylation levels of MyBP-C measured by phosphate affinity SDS-PAGE
using the technique of Copeland et al. (2010). See supplement for details of method. (C) Histogram of troponin I phosphorylation levels in cat myofibrils measured by
phosphate affinity SDS-PAGE using the technique of Messer et al. (2009). See supplement for details of method. Blue bars, non-HCM cat samples; red bars, HCM
cat samples.
donor heart muscle. In human myectomy samples, MyBP-C
phosphorylation is substantially reduced (1.05 ± 0.13 mols
Pi/mol; Messer et al., 2009).
Although some cat HCM samples, notably H6 and H17,
appeared dephosphorylated, the majority of cat HCM samples
had phosphorylation levels comparable with non-HCM cat
samples. When all the cats were averaged, there was no
significant overall reduction of cMyBP-C phosphorylation in
the HCM samples (mean = 2.32 ± 0.95 mols Pi/mol, n
= 17, p = 0.22) in contrast to the human myectomy
samples.
Phosphorylation assessments of feline troponin I (TnI)
showed similar results to MyBP-C. Certain samples appeared
dephosphorylated (H2 and H10), but there was no overall
significant difference between the normal and hypertrophic
groups (Non-HCM: mean = 1.49 ± 0.17 mols Pi/mol TnI,
n = 8; HCM: mean = 1.46 ± 0.12 mols Pi/mol TnI, n =
18, p = 0.874; Figure 3C). This is very different from human
heart where donor heart muscle has a phosphorylation level
similar to non-HCM cat (1.62 ± 0.06 mols Pi/mol TnI) but
myectomy samples have a very low level of phosphorylation
(0.26 ± 0.02 mols Pi/mol TnI) (Messer et al., 2009; Bayliss
et al., 2012). The low levels of TnI or MyBP-C phosphorylation
in some of the cat samples may be a consequence of the
post-mortem treatment of the cat hearts although we did not
detect any correlation between the time of storage at −20◦C
prior to −80◦C freezing and the level of TnI or MyBP-C
phosphorylation.
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TABLE 2 | Analysis of MyBP-C haploinsufficiency in HCM cat heart muscle.
Sample Mean Percentage Significance Repeats
cMyBP-C relative deficiency (p) (n)
to non-HCM of MyBP-C
H6 0.79 21 <0.05 12
H7 0.70 30 <0.001 6
H8 0.78 22 <0.05 6
H10 0.78 22 <0.05 6
H14 0.56 44 <0.05 6
H16 0.81 19 <0.001 6
Non-HCM and HCM cat samples were compared by one-way ANOVA and 5 samples
showed significant haploinsuffficiency. * p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. H16 is close
to significance in the ANOVA test and is significant in a paired t-test when compared with
non-HCM samples in the same gel.
Thin Filaments from HCM Cats have Higher
Ca2+-Sensitivity than Non-HCM Cats
To study Ca2+ regulation of contraction, we extracted troponin
from cat hearts using the protocols we have developed for
human heart troponin. Yields were comparable to human and the
troponin was fully competent at regulating thin filaments in the
quantitative in vitro motility assay (IVMA). We investigated the
Ragdoll (MYBPC3 R820W mutation) (H5) cat heart troponin in
detail and also studied troponin from 7 other cats that had a high
confidence of HCM diagnosis (see Table 1).
Figure 4A shows an example of the Ca2+ titration curves
of HCM cat H5 compared to a non-HCM cat, N4; both had
a naturally high level of troponin phosphorylation (Figure 3C).
The left shifted Ca2+ curves of both sliding speed and fraction
motile and the calculated lower EC50 indicates that the HCM
FIGURE 4 | Ca2+-sensitivity of HCM cat and human compared with non-HCM control. The sliding speed (top graphs) and fraction of filaments motile (bottom
graphs), measured in paired experiments by IVMA is plotted against [Ca2+] for representative single experiments. HCM and non-HCM samples are compared. (A)
Example of cat heart troponin; cTnI in both N4 and H5 troponins are fully phosphorylated. (B) example of human heart troponin; cTnI in normal troponin is fully
phosphorylated whilst HOCM troponin is unphosphorylated. Blue lines and points, non-HCM troponin (cat N4 and human NK), red lines and points, HCM troponin
(cat H5 and human MR). The Hill equation is fitted to the data (solid lines) to yield values of EC50 and nH. The mean values of replicate experiments are shown in
Figure 5 for cats and Supplementary Table S2 for humans.
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FIGURE 5 | Summary of EC50 in non-HCM and HCM cat troponin. Mean
EC50 ± sem is shown for at least three replicate determinations of
Ca2+-sensitivity for non-HCM cat troponin (blue) and HCM cat troponin (red)
as shown in Figure 3A. All the HCM cat samples have a higher
Ca2+-sensitivity than non-HCM samples. See Supplementary Table S6 for full
details.
cat has a 1.5–2.0 fold higher Ca2+-sensitivity than non-HCM
cat troponin. This was confirmed with a total of 6 H5 troponin
preparations, compared with 2 different non-HCM troponins
(mean non-HCM EC50 = 0.094 ± 0.005 µM, mean H5 EC50 =
0.045 ± 0.004, mean EC50 non-HCM/EC50 H5 = 2.19 ± 0.27,
p= 0.008).
Ca2+-sensitivity of HCM cat troponin was tested in
seven further cats, including two that showed MyBP-C
haploinsufficiency (H7 and H14), all of which showed a higher
Ca2+-sensitivity than non-HCM troponin in paired (non-HCM
+ HCM) assays combining fraction motile and sliding speed at
similarly high levels of troponin phosphorylation (mean non-
HCM EC50 = 0.090 ± 0.005 µM, mean all HCM troponin
EC50 = 0.046 ± 0.003, mean EC50 non-HCM/EC50 HCM =
2.05 ± 0.13, n = 7, p < 0.0001), see Figure 5 and Table 3. There
were no significant differences in nH and maximum sliding speed
between non-HCM and HCM cat troponin.
Modulation of Cat Troponin
Ca2+-Sensitivity by TnI Phosphorylation
In man and mouse, the Ca2+-sensitivity of normal heart muscle
troponin is modulated by TnI phosphorylation at Ser 22 and 23
by PKA. This was also true for the non-HCM cat heart samples.
Phosphorylation levels were manipulated by dephosphorylating
highly phosphorylated troponin and treating unphosphorylated
troponin with PKA+ATP. Figure 6A shows the Ca2+-activation
curve for a typical non-HCM cat troponin in the phosphorylated
and unphosphorylated states; there is an∼2-fold increase in EC50
upon phosphorylation. The same pattern of results was found
with all five cat hearts tested (see Figure 7 and Table 2).
We have frequently found that the Ca2+-sensitivity of
troponin extracted from the heart muscle of patients with
HCM obtained from myectomy operations is not modulated by
phosphorylation (Supplementary Table S3; Bayliss et al., 2012;
Messer et al., 2016). This also occurred in our HCM cat troponin
samples; Figure 6B illustrates this for cat H5. The insensitivity
of Ca2+-sensitivity to the level of TnI phosphorylation was
found for every HCM cat troponin, irrespective of the causative
mutation (Figure 7 and Table 3).
Blunted Modulation of Ca2+-Sensitivity by
TnI Phosphorylation in HCM Cats Can Be
Restored by Adding EGCG
In studies using human and mouse heart muscle we found that
coupling could be restored to HCM thin filaments by adding
small molecules such as Epigallocatechin-3-gallate (EGCG) and
Silybin (Bayliss et al., 2012; Papadaki et al., 2015; Messer et al.,
2016). We tested whether recoupling could be observed in cat
heart troponin.
When 100µM EGCG was added to troponin from H5
cat heart it restored coupling in reconstituted thin filaments
measured by IVMA (Figure 8A). EGCG did not affect the EC50
of unphosphorylated H5 troponin but it increased the EC50
of phosphorylated H5 troponin, thus restoring EC50 to the
values present in the non-HCM cat. The change in EC50 on
phosphorylation in the presence of EGCG was 2.21 ± 0.16 fold
in four separate assays with H5. EGCG also recoupled troponin
from H13 and H14 cat hearts by a similar amount (see Table 3).
Figure 8B shows the restoration of EC50 to normal by EGCG
with H13.
In previous studies of HCM in human myectomy samples we
observed that it was possible to restore coupling by replacing
troponin T (TnT) with wild-type (human) recombinant TnT.
We tested whether this also occurred with HCM cat troponin.
When we replaced TnT in troponin from the Ragdoll MYBPC3
R820W H5 cat heart with wild-type (human) recombinant TnT
by an exchange reaction we found that the modulation of Ca2+-
sensitivity by TnI phosphorylation was restored (Supplement S3
and Table 3). The change in EC50 on phosphorylation was 1.61±
0.01 fold, comparable with the same experiment in HCM human
heart troponin (1.85 ± 0.13 fold) and with the phosphorylation
effect on EC50 in non-HCM cat (Figure 6).
DISCUSSION
HCM in cats has been recognized for over 30 years and its
parallels with HCM in humans have been previously described
(Kittleson et al., 1999; Maron and Fox, 2015). HCM in humans
is a highly complex and heterogeneous disease at the genetic,
cellular, and clinical level. Disease-causing mutations in myosin
heavy chain 7 (MYH7) and cardiac myosin binding protein C
(MYBPC3) genes, account for ∼70% of identified pathogenic
alleles (Maron et al., 2006). Pathogenic alleles that do not encode
for sarcomeric proteins have also been identified in some HCM
patients however their role remains controversial (Cecconi et al.,
2016; Walsh et al., 2017). Mutations in genes responsible for
metabolic storage disorders with a clinical presentation and
pattern of left-ventricular hypertrophy similar to HCM are
also recognized. Furthermore, pathogenic alleles have not been
identified in 28–40% of HCM patients with a family history
of HCM and 50–90% of sporadic HCM cases (Cecconi et al.,
2016). Despite this complexity, mutations in sarcomeric proteins
Frontiers in Physiology | www.frontiersin.org 11 June 2017 | Volume 8 | Article 348
Messer et al. Hypertrophic Cardiomyopathy in Cats
T
A
B
L
E
3
|
E
ff
e
c
ts
o
f
m
u
ta
tio
n
s
a
n
d
p
h
o
sp
h
o
ry
la
tio
n
o
n
C
a
2
+
-s
e
n
si
tiv
ity
o
f
th
in
fil
a
m
e
n
ts
c
o
n
ta
in
in
g
tr
o
p
o
n
in
fr
o
m
H
C
M
c
a
t
h
e
a
rt
s.
C
A
T
A
ll
N
o
n
-H
C
M
H
1
H
2
H
3
H
5
H
7
H
1
2
H
1
3
H
1
4
A
ll
H
C
M
E
C
5
0
,
µ
M
±
S
E
M
,
n
a
n
d
p
-v
a
lu
e
(U
n
p
a
ire
d
t-
te
st
re
la
tiv
e
to
n
o
n
-H
C
M
)
S
lid
in
g
sp
e
e
d
0
.0
9
2
±
0
.0
0
6
0
.0
6
0
±
0
.0
1
0
0
.0
4
3
±
0
.0
0
4
0
.0
8
3
±
0
.0
1
2
0
.0
5
6
±
0
.0
0
3
0
.0
3
7
±
0
.0
0
2
0
.0
5
4
±
0
.0
0
2
0
.0
4
8
±
0
.0
1
5
0
.0
5
4
±
0
.0
1
0
0
.0
5
7
±
0
.0
0
3
n
=
2
4
n
=
2
n
=
3
n
=
6
n
=
1
9
n
=
3
n
=
4
n
=
2
n
=
5
n
=
4
4
p
=
0
.1
3
6
p
=
0
.0
0
8
0
p
=
0
.4
9
p
<
0
.0
0
0
1
p
=
0
.0
0
3
2
p
=
0
.0
1
5
p
=
0
.0
4
7
p
=
0
.0
0
9
5
p
<
0
.0
0
0
1
F
ra
c
tio
n
m
o
til
e
0
.0
7
2
±
0
.0
0
4
0
.0
4
0
±
0
.0
0
7
0
.0
3
9
±
0
.0
0
4
0
.0
3
6
±
0
.0
0
1
0
.0
5
0
±
0
.0
0
2
0
.0
2
9
±
0
.0
0
1
0
.0
3
3
±
0
.0
0
3
0
.0
2
8
±
0
.0
0
2
0
.0
5
3
±
0
.0
0
8
0
.0
4
3
±
0
.0
0
2
n
=
2
6
n
=
2
n
=
3
n
=
6
n
=
1
9
n
=
4
n
=
4
n
=
3
n
=
5
n
=
4
6
p
=
0
.0
1
1
p
=
0
.0
0
0
2
p
<
0
.0
0
0
1
p
=
0
.0
0
0
3
p
=
0
.0
0
0
8
p
=
0
.0
0
1
1
p
=
0
.0
6
1
p
<
0
.0
0
0
1
E
C
5
0
P
/u
n
P
±
S
E
M
,
n
a
n
d
p
-v
a
lu
e
(S
in
g
le
va
lu
e
s
c
o
m
p
a
re
d
w
ith
1
)
S
lid
in
g
sp
e
e
d
1
.8
3
3
±
0
.1
1
2
1
.0
9
1
±
0
.1
1
8
0
.9
8
8
±
0
.0
4
9
1
.0
6
8
±
0
.0
8
8
1
.0
9
8
±
0
.0
3
3
0
.9
5
7
±
0
.0
2
1
1
.0
1
0
±
0
.1
1
2
0
.9
9
1
0
.9
9
7
±
0
.1
2
2
1
.0
5
0
±
0
.0
2
3
n
=
8
n
=
2
n
=
3
n
=
3
n
=
1
0
n
=
2
n
=
2
n
=
1
n
=
2
n
=
2
5
p
=
0
.0
0
0
1
p
=
0
.8
2
p
=
0
.5
2
p
=
0
.0
1
5
p
=
0
.0
3
7
F
ra
c
tio
n
m
o
til
e
1
.7
9
6
±
0
.0
5
5
1
.0
0
6
±
0
.0
8
0
0
.9
6
0
±
0
.0
5
4
1
.0
0
1
±
0
.0
1
5
1
.1
1
3
±
0
.0
4
8
1
.0
5
1
±
0
.0
4
8
0
.9
3
5
±
0
.0
2
2
1
.0
4
8
±
0
.0
1
3
0
.8
3
8
±
0
.0
0
2
3
1
.0
3
0
±
0
.0
2
6
n
=
9
n
=
2
n
=
3
n
=
3
n
=
1
0
n
=
2
n
=
2
n
=
2
n
=
2
n
=
2
6
p
<
0
.0
0
0
1
p
=
0
.5
3
p
=
0
.9
4
p
=
0
.0
4
4
p
=
0
.2
6
1
0
0
µ
M
E
G
C
G
E
C
5
0
P
/u
n
P
±
S
E
M
,
n
a
n
d
p
-v
a
lu
e
(U
n
p
a
ire
d
t-
te
st
re
la
tiv
e
to
u
n
tr
e
a
te
d
)
S
lid
in
g
sp
e
e
d
2
.3
2
2
.1
9
7
±
0
.1
5
8
3
.3
7
7
1
.4
0
3
2
.2
6
1
±
0
.2
7
7
n
=
1
n
=
4
n
=
1
n
=
1
n
=
6
–
p
<
0
.0
0
0
1
–
–
p
<
0
.0
0
0
1
F
ra
c
tio
n
m
o
til
e
1
.5
4
1
.8
9
8
±
0
.2
2
5
1
.9
2
7
1
.3
1
3
1
.8
0
5
±
0
.1
7
3
n
=
1
n
=
4
n
=
1
n
=
1
n
=
6
–
p
=
0
.0
0
0
2
7
–
–
p
<
0
.0
0
0
1
T
n
T
e
x
c
h
a
n
g
e
E
C
5
0
P
/u
n
P
±
S
E
M
,
n
a
n
d
p
-v
a
lu
e
(U
n
p
a
ire
d
t-
te
st
re
la
tiv
e
to
u
n
tr
e
a
te
d
)
S
lid
in
g
sp
e
e
d
1
.6
9
6
±
0
.0
3
6
n
=
3
p
<
0
.0
0
0
1
F
ra
c
tio
n
m
o
til
e
1
.6
4
4
±
0
.0
5
2
n
=
3
p
=
0
.0
0
0
1
6
T
h
e
E
C
5
0
o
f
th
in
fil
a
m
e
n
ts
fr
o
m
n
o
n
-H
C
M
a
n
d
H
C
M
c
a
ts
is
c
o
m
p
a
re
d
a
n
d
th
e
e
ff
e
c
t
o
f
T
n
Ip
h
o
s
p
h
o
ry
la
ti
o
n
o
n
E
C
5
0
is
p
lo
tt
e
d
fo
r
a
s
e
ri
e
s
o
f
d
iff
e
re
n
t
H
C
M
c
a
t
s
a
m
p
le
s
,
u
s
in
g
IV
M
A
.
T
h
e
la
s
t
tw
o
ro
w
s
s
h
o
w
h
o
w
c
o
u
p
lin
g
c
a
n
b
e
re
s
to
re
d
b
y
e
xc
h
a
n
g
e
o
f
T
n
T
w
it
h
w
ild
-t
yp
e
(h
u
m
a
n
s
e
q
u
e
n
c
e
)
T
n
T
o
r
b
y
E
G
C
G
.
P
-v
a
lu
e
s
a
re
g
iv
e
n
u
s
in
g
S
tu
d
e
n
ts
’s
t-
te
s
t
fo
r
H
C
M
c
o
m
p
a
re
d
w
it
h
n
o
n
-H
C
M
o
r
fo
r
th
e
ra
ti
o
o
f
E
C
5
0
in
p
h
o
s
p
h
o
ry
la
te
d
/u
n
p
h
o
s
p
h
o
ry
la
te
d
tr
o
p
o
n
in
c
o
m
p
a
re
d
w
it
h
1
.
F
u
ll
d
e
ta
ils
o
f
th
e
IV
M
A
e
xp
e
ri
m
e
n
ts
a
re
s
u
m
m
a
ri
ze
d
in
S
u
p
p
le
m
e
n
ta
ry
Ta
b
le
S
6
.
Frontiers in Physiology | www.frontiersin.org 12 June 2017 | Volume 8 | Article 348
Messer et al. Hypertrophic Cardiomyopathy in Cats
FIGURE 6 | Modulation of Ca2+-sensitivity by TnI phosphorylation in non-HCM and HCM cat. Sliding speed (top graphs) and fraction of filaments motile (bottom
graphs) was measured with phosphorylated and unphosphorylated troponin by IVMA. Ca2+ dependence of motility is plotted against [Ca2+] for representative single
experiments. (A) Phosphorylated and unphosphorylated non-HCM cat troponin (N4), (B) phosphorylated and unphosphorylated HCM cat troponin (H5). The Hill
equation is fitted to the data to yield values of EC50 and nH Solid lines, phosphorylated; dotted lines, unphosphorylated. The mean ratios of EC50 values from
replicate experiments is shown in Figure 6 and Table 3. Full data is shown in Supplementary Table S3.
remain the most established and well-studied cause of HCM in
humans.
The role of genetic mutations in feline HCM is less well-
characterized since to date only two causative mutation have
been identified, both in MYBPC3 (Meurs et al., 2007; Longeri
et al., 2013) and the prevalence of phenocopies and moderator
genes remains unclear. In the absence of substantial genetic
information, we postulated that exploration of feline HCM at the
sarcomeric level may identify common regulatory characteristics
driving the disease phenotype between species.
In this study, we have investigated left ventricular tissue
from 18 cats diagnosed with HCM, including one Ragdoll
cat heart with a homozygous MYBPC3 R820W mutation, in
comparison with seven non-HCM cat hearts. Tissue was obtained
immediately following euthanasia with owner consent. The cat
hearts were also compared with human heart tissue (septal
myectomies from HCM patients and donor hearts as non-HCM
controls).
When separated on SDS-PAGE the myofibrils of non-
HCM and HCM cat hearts appeared indistinguishable from
human heart myofibrils. However, when we examined the
expression level of MyBP-C protein relative to α-actinin we
found that five of the HCM cats had significantly reduced
expression levels, compared with non-HCM cats or the other
13 HCM cats. In man it has been demonstrated that many
HCM-causing mutations in MYBPC3, especially truncating
mutations, produce a comparable haploinsufficiency of up to
25% (Marston et al., 2009, 2011; Van Dijk et al., 2009).
Moreover, it has been proposed that haploinsufficiency is
sufficient to cause the increased myofilament Ca2+-sensitivity
characteristic of HCM. This result would therefore suggest
that the HCM cats H6, H7, H8, H10, H14 (four outbred
cats and one Bengal) and possibly H16 may have disease-
causing mutations in MYBPC3. Unfortunately, we do not
know the genotypes our cohort of HCM cats other than
confirmation that the Ragdoll cat, H5, had a homozygous
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MYBPC3 R820W mutation and that the Maine Coon cat, H16,
did not have the MYBPC3 A31P mutation. Other groups have
likewise encountered great difficulty in genotyping cats with
HCM so the question of MYBPC3 mutations in the cats with
haploinsufficiency remains unresolved at the moment (Meurs
et al., 2009).
Surprisingly, the MYBPC3 R820W mutation in H5 was not
associated with any haploinsufficiency, indicating that this is not
FIGURE 7 | Effect of phosphorylation on Ca2+-sensitivity in non-HCM and
HCM cat. The mean ratio of EC50 phosphorylated:EC50 unphosphorylated ±
sem is plotted for at least three replicate experiments for non-HCM cat
troponin (blue) and HCM cat troponin (red). A ratio of 1 (dotted line) indicates
uncoupling. Full data is shown in Supplementary Table S3.
an exclusive disease-causing pathway for MYBPC3 mutations.
A recent study also failed to identify haploinsufficiency
in Maine Coon cats with the A31P mutation (van Dijk
et al., 2016), indicating that a poison polypeptide mechanism
may be involved in HCM due to MYBPC3 mutations in
homozygous Ragdoll and Maine Coon cats. HCM not associated
with MyBP-C haploinsufficiency has also been noted in
some human cases with MYBPC3 mutations (Helms et al.,
2014).
Investigations of HCM in humans with known sarcomeric
mutations compared with non-HCM hearts indicates that
the primary abnormality induced by the mutation is likely
to be enhanced Ca2+-sensitivity, usually accompanied by an
uncoupling of the relationship between TnI phosphorylation
and modulation of Ca2+-sensitivity (Marston, 2011, 2016). Our
studies of HCM and non-HCM cat hearts likewise showed clear
differences between the HCM and non-HCM samples with a
100% correspondence between HCM diagnosis and abnormality
of Ca2+-regulation. We found that thin filaments containing
HCM cat troponin always had a 1.5–2.5 fold higher Ca2+-
sensitivity than the non-HCM containing thin filaments. This
effect is as predicted for HCM-related mutations and is evidently
independent of the mutated gene, which in most cases was
unknown.
Interestingly, we also found that Ca2+-sensitivity in non-
HCM cat thin filaments was modulated by TnI phosphorylation
but not in any of the HCM cat samples. This “uncoupling”
phenomenon, independent of the HCM-causing mutation has
been noted before in humanHCM andmay be a common feature
FIGURE 8 | Recoupling of HCM cat thin filaments by EGCG. (A) The effect of 100 µM EGCG on cat HCM sample H5 measured by IVMA. The Hill equation is fitted to
the data to yield values of EC50 and nH. Solid symbols and lines, phosphorylated; open symbols and dotted lines, unphosphorylated. Red points and lines are in the
absence and green points and lines are in the presence of EGCG. EGCG reduces the Ca2+-sensitivity of phosphorylated but not unphosphorylated H5 troponin and
thus restores coupling. (B) Demonstration of complete restoration of coupling by EGCG. The figure shows the phosphorylated and unphosphorylated EC50 of the
non-HCM cat sample N12 (coupled) and the HCM cat sample H13 (uncoupled). Addition of EGCG to H13 restores phosphorylation-dependence of EC50 to H13. Full
data in Supplementary Table S5.
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of HCMheart muscle even when themutation is not in one of the
troponin genes (Bayliss et al., 2012; Messer and Marston, 2014;
Messer et al., 2016).
These observations of increased Ca2+-sensitivity of troponin
together with uncoupling, found in all eight HCM cats, are
surprising since mutations in troponin I, C, or T, are rare causes
of HCM in human and presumably also in cats; indeed the
only identified mutation is in MyBP-C. It has been reported
that HCM mutations in MYBPC3, MYH7, and MYL2 cause
enhanced myofibrillar Ca2+-sensitivity in muscle strips (see
Marston, 2016). This was presumed to be due to allosteric
interactions between the thick and thin filaments, however the
results with the cat samples indicates that troponin is itself
altered secondary to the HCM mutations in another gene. It
is likely that the Ca2+-sensitivity difference and uncoupling
found in HCM troponin are related. The Ca2+-sensitivity of
phosphorylated and unphosphorylated HCM cat troponin (EC50
= 0.046 ± 0.004 and 0.046 ± 0.004 µM, respectively) are
equal to the Ca2+-sensitivity of unphosphorylated non-HCM cat
troponin (EC50 = 0.042 ± 0.004) and are higher than that of
phosphorylated non-HCM cat troponin. (EC50 = 0.090± 0.005),
thus accounting for the difference in Ca2+-sensitivity observed
when phosphorylated HCM and non-HCM cat troponin are
compared (Supplementary Tables S4, S5). The apparent lack of a
Ca2+-sensitivity difference observed with the human samples is
due to the different phosphorylation levels of donor and HOCM
troponin in this experiment (Figure 4B).
Experiments with troponin from human myectomy samples
offer a partial explanation for these observations although further
studies of human HCM samples need to be done to match
those done with the cat. Supplementary Table S3 shows tests on
six different human myectomy samples, five with no identified
mutation and one with a MYBPC3 mutation all of which
show that the troponin Ca2+-sensitivity is not coupled to TnI
phosphorylation level. The mechanism by which mutations not
in thin filament proteins can produce uncoupling of the thin
filament has not been resolved. We found that in the human
myectomy samples the uncoupling was due to a secondary
abnormality of TnT (Bayliss et al., 2012); despite extensive
investigation, the nature of the presumed post-translational
modifications of cTnT has not been found. It is, however,
noteworthy that we have also been able to restore coupling
in troponin from HCM cat by replacing TnT with wild-type
(human) recombinant protein indicating that the same process
operates in feline HCM (Supplementary Figure S4). Similarities
between cat and humanHCM are emphasized by the observation
that the enhanced Ca2+-sensitivity and uncoupling due to HCM
mutations can be reversed by 100 µM EGCG in the cat as has
been previously demonstrated in human heart muscle (Papadaki
et al., 2015).
This study shows the most established mechanism identified
in humans with HCM: enhanced myofilament Ca2+-sensitivity
and uncoupling, was present in all the feline myocardial samples
tested. This finding would suggest that the disease in these
cats was probably caused by mutations in myofilament proteins
especially in light of the established heritability of HCM in
several cat breeds (Nakagawa et al., 2002; Chetboul et al., 2012;
Silverman et al., 2012; März et al., 2014). It is noteworthy
that the mutations currently known only cause severe disease
and reduced survival in homozygous cats (Borgeat et al.,
2014; Granström et al., 2015) whilst the majority of human
HCM is cases have heterozygous mutations. Whilst MYBPC3
mutations have been identified in Maine Coon and Ragdoll cats,
the causative mutation in Norwegian Forest, British Shorthair,
Siberian, Sphynx, American Shorthair, Cornish Rex, Persian,
Bengal, and Chartreux cats, or in any hybrid domestic shorthair
cats has not been identified despite having the same disease
phenotype (Meurs et al., 2009). The difficulty in determining
mutations in cat genes is likely due to the sparsity of sequenced
genomes. The canonical sequences of many sarcomeric proteins
have not been verified by multiple independent determinations
and the pattern of non-pathogenic variants is thus unknown
(Montague et al., 2014).
The differences between the properties of the cat HCM
samples and myectomy samples (level of TnI and MyBP-C
phosphorylation and Ca2+-sensitivity relative to donor troponin)
may relate to the different origin of the tissues sampled. The feline
tissue was full thickness and obtained from the left ventricular
free wall taken midway between the apex and atrioventricular
groove. This area of the left ventricle is not subjected to
the remodeling effect of the chronic impact of the anterior
mitral leaflet during systole and associated turbulent blood flow
which occurs in the basilar interventricular septum (IVS) from
where myectomy samples are obtained. Significant replacement
and interstitial fibrosis together with marked small intramural
coronary arteriole dysplasia and myofiber disarray is common in
the basal IVS for hearts with obstructive disease and may exceed
that seen in the rest of the left ventricle (Fox, 2003; Moravsky
et al., 2013). Alternatively, the difference may relate to the stage
of disease when the samples were taken. Myectomy is performed
to alleviate the left ventricular outflow tract obstruction, reduce
myocardial work and thereby prolong survival (Maron and
Maron, 2016). It is therefore performed in patients who still
have adequate myocardial systolic function. The procedure is
not available in cats and the feline samples were obtained from
animals euthanized presenting with intractable heart failure,
aortic thromboembolism or output failure due to advanced
disease.
The study described here has strengthened the proposition
that HCM in the cat is a close analog of human HCM and thus
a potentially useful large animal model. The major constraint
to fully exploiting the feline model of HCM is the sparsity
of information about disease-causing mutations in sarcomeric
and non-sarcomeric genes as described above. In addition the
prevalence of HCM phenocopies and influence of modifier
genes is unknown. Despite this, feline HCM has a number
of significant advantages over engineered rodents as a natural
proof of concept model for novel therapies due to a closer
gene and protein expression profile and cardiac physiology
between the cat and the human. In addition, the heterogeneous
expression of the feline disease closely mimics human HCM due
to the wider genetic background of cats compared to inbred
mice. Finally, whilst the pathological changes characteristic of
HCM may take several decades to develop in humans, the rate
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of progression of disease in cats generally occurs over a 2–
5 year timescale enabling potential therapies to be assessed in
an economically acceptable timeframe. The feline model shows
promise in drug development; for instance, the effects of EGCG
are essentially identical in man and cat (Papadaki et al., 2015)
and the myosin inhibitor MYK-451 has been shown to exert the
predicted acute physiological effect on HCM cats (Stern et al.,
2016).
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